$PBIO Uptick Newswire Hosts Pressure BioSciences, Inc. on the Stock Day Podcast to Discuss Their (1) Just Announced Collaboration With NutraFuels, Inc., (2) the Commercial Launch of Their BioPharmaceuticals Contract Services Business, and (3) the Publication ofPress Release | 02/04/2019
PHOENIX, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" or the "Company"
, a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, to update Stock Day’s listeners on PBI’s three recent press releases. The Company’s President and CEO, Mr. Richard T. Schumacher, joined Stock Day’s Mr. Everett Jolly to discuss their recent successes.
Mr. Jolly began the interview by asking Mr. Schumacher to explain to new listeners the Company’s products and how the Company generates revenue. “We are a life science company. We sell instruments, consumables, and services to other life science companies all over the world. We have three patented technologies (about twenty-five issued patents) that all rely on pressure. We’ve been able to harness high pressure and bring it into the laboratory, which has never really been done at these levels before,” answered Mr. Schumacher.
Mr. Schumacher further explained that the ability to harness high pressure allows scientific researchers to manipulate biological samples in ways that are difficult or even impossible to do with other technologies. This helps scientists in their research, which potentially could result in the discovery of new drugs, vaccines, biomarkers, and preventive strategies.
Mr. Jolly then asked, “It seems as though your patents would be a huge breakthrough for technology in the cannabinoid industry. Do you have any thoughts about that?”
Mr. Schumacher replied, “CBD, CBG, and other cannabinoids are all part of a big industry called nutraceuticals, whose products include such items as dietary supplements, nutrients, and herbal products. NutraFuels is a small, rapidly growing nutraceuticals company whose products are used to help alleviate pain, anxiety, weight loss, sleep disorders, and other issues. Our announcement on Wednesday, January 30th was to publicly disclose the collaboration we have entered into with NutraFuels, a collaboration that will use PBI’s proprietary pressure-based Ultra Shear Technology (UST) platform to try and increase the quality of NutraFuels existing and future products.”
Mr. Schumacher explained that NutraFuels’ products in the anti-aging, anti-pain, and anti-anxiety space include products with and without CBD. While this company is growing rapidly, they are being very cautious as they will settle for nothing less than to produce their products in the best possible way. This is where PBI’s patented UST platform comes into play.
Mr. Schumacher explained, “If you think about CBD-infused and other nutraceuticals, many of these compounds are extracted from plants and are recovered in oils. Unfortunately, human bodies do not absorb oils very efficiently. What we do is process the plant oil (containing the nutraceutical) by our UST platform, which uses a unique combination of high pressure and ultra-sonic shearing (or cutting). Using this process, we actually cut the oil drops (with the nutraceutical) from very large sizes down to very small droplets. These small droplets of oil mixed with water (called nanoemulsions) contain the compound of interest. In some cases, it is CBD, but it might well be some other compound, such as a vitamin or nutrient. Once the oil drops have been sheared to very small, nano-sized droplets, it can be added to an edible or drink for delivery. Because of their nano-size, the human body will absorb the compounds in the nano-droplets much more efficiently. In fact, in the case of CBD, it is believed that less than 10% of CBD is absorbed from normally processed plant oil (usually a macroemulsion), but that as much as 80-90% or more can be absorbed if the CBD-plant oil is ingested in the form of a nanoemulsions. It is universally believed that nanoemulsions are the most effective route to take in the production of CBD-infused products.”
As part of its collaboration, PBI plans to optimize the current compounds at NutraFuels Inc. using nanoemulsion technology based on their UST platform, to take what is already seen as a high-quality product and make it even higher in quality.
Mr. Jolly noted that the Company’s UST platform could be a major “game-changer” and that in his professional opinion the Company is grossly undervalued.
Mr. Jolly then asked Mr. Schumacher about the Company’s recent announcement involving the commercial launch of an entirely new service line called BioPharmaceutical Contract Services. Mr. Schumacher explained that in December 2017, the Company purchased the patent estate of Barofold, Inc. that had spent around $25 million to develop technology involving pressure to control and improve protein molecules being used to make drugs. The patents purchased from Barofold allow the Company to exclusively use different levels of pressure to help fix problems that biopharmaceutical companies often run into as they try to manufacture new protein-based drugs, a very large and growing market with over 200 such drugs already on the market and hundreds more in development. Two of the major problems encountered by such manufacturers are (i) the proteins stick together (aggregation) thus making them not useful as drugs, and (ii) the proteins are “misfolded” (their structure is incorrect). Both of these issues could potentially cause the manufacturers to discard millions of dollars of product from production lots that have aggregation or misfolding issues. Sometimes these issues are so bad that biopharma companies can’t even get the drug to market in the first place. The good news is that PBI’s new Barofold platform can sometimes fix these issues. This is the basis of PBI’s new biopharmaceutical services business, which the Company believes will add significantly to the Company’s revenue in 2019 and beyond.
Mr. Schumacher stated, “We’re going to start advertising, talking to companies, and actively bringing in business, because we know we can help a number of companies who are struggling with protein-based drugs in development get to market. We also believe we can help companies that are already on the market stay on the market, should they encounter aggregation or misfolding issues, as often occurs during manufacturing.”
Mr. Jolly then inquired about the numerous scientific articles published during 2018 that highlighted the benefits of the Company’s Pressure Cycling Technology (PCT) platform. Mr. Schumacher explained that scientific publications from peers are highly respected among researchers and that the fact that over 20 publications were released during 2018 regarding PBI’s PCT technology, some from globally-renowned protein and nucleic acid scientists, will add great support to PBI’s sales and marketing efforts, and should help the Company as it looks to increase its revenue during 2019 and beyond.
Mr. Schumacher closed by stating, “We are a time-tested company with patents, products, a tremendous customer base, an expanding market, and increasing sales. We have struggled a bit over the past few years for a number of different reasons, but we believe we are past that now and on the road to success. Our three pressure-based technology platforms have been vetted by key opinion leaders globally, we have a number of leading scientists in the world who are using our various products, and we expect increased revenue in 2019 from our two new platform technologies (Barofold and UST). We believe that PBIO shareholders have much to be excited about going forward.”
To hear Mr. Schumacher's entire interview with Stock Day, please go here: https://upticknewswire.com/featured-interview...b-pbio-11/
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
About Pressure BioSciences, Inc.
PHOENIX, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" or the "Company" , a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, to update Stock Day’s listeners on PBI’s three recent press releases. The Company’s President and CEO, Mr. Richard T. Schumacher, joined Stock Day’s Mr. Everett Jolly to discuss their recent successes. Mr. Jolly began the interview by asking Mr. Schumacher to explain to new listeners the Company’s products and how the Company generates revenue. “We are a life science company. We sell instruments, consumables, and services to other life science companies all over the world. We have three patented technologies (about twenty-five issued patents) that all rely on pressure. We’ve been able to harness high pressure and bring it into the laboratory, which has never really been done at these levels before,” answered Mr. Schumacher.
Mr. Schumacher further explained that the ability to harness high pressure allows scientific researchers to manipulate biological samples in ways that are difficult or even impossible to do with other technologies. This helps scientists in their research, which potentially could result in the discovery of new drugs, vaccines, biomarkers, and preventive strategies.
Mr. Jolly then asked, “It seems as though your patents would be a huge breakthrough for technology in the cannabinoid industry. Do you have any thoughts about that?”
Mr. Schumacher replied, “CBD, CBG, and other cannabinoids are all part of a big industry called nutraceuticals, whose products include such items as dietary supplements, nutrients, and herbal products. NutraFuels is a small, rapidly growing nutraceuticals company whose products are used to help alleviate pain, anxiety, weight loss, sleep disorders, and other issues. Our announcement on Wednesday, January 30th was to publicly disclose the collaboration we have entered into with NutraFuels, a collaboration that will use PBI’s proprietary pressure-based Ultra Shear Technology (UST) platform to try and increase the quality of NutraFuels existing and future products.”
Mr. Schumacher explained that NutraFuels’ products in the anti-aging, anti-pain, and anti-anxiety space include products with and without CBD. While this company is growing rapidly, they are being very cautious as they will settle for nothing less than to produce their products in the best possible way. This is where PBI’s patented UST platform comes into play.
Mr. Schumacher explained, “If you think about CBD-infused and other nutraceuticals, many of these compounds are extracted from plants and are recovered in oils. Unfortunately, human bodies do not absorb oils very efficiently. What we do is process the plant oil (containing the nutraceutical) by our UST platform, which uses a unique combination of high pressure and ultra-sonic shearing (or cutting). Using this process, we actually cut the oil drops (with the nutraceutical) from very large sizes down to very small droplets. These small droplets of oil mixed with water (called nanoemulsions) contain the compound of interest. In some cases, it is CBD, but it might well be some other compound, such as a vitamin or nutrient. Once the oil drops have been sheared to very small, nano-sized droplets, it can be added to an edible or drink for delivery. Because of their nano-size, the human body will absorb the compounds in the nano-droplets much more efficiently. In fact, in the case of CBD, it is believed that less than 10% of CBD is absorbed from normally processed plant oil (usually a macroemulsion), but that as much as 80-90% or more can be absorbed if the CBD-plant oil is ingested in the form of a nanoemulsions. It is universally believed that nanoemulsions are the most effective route to take in the production of CBD-infused products.”
As part of its collaboration, PBI plans to optimize the current compounds at NutraFuels Inc. using nanoemulsion technology based on their UST platform, to take what is already seen as a high-quality product and make it even higher in quality.
Mr. Jolly noted that the Company’s UST platform could be a major “game-changer” and that in his professional opinion the Company is grossly undervalued.
Mr. Jolly then asked Mr. Schumacher about the Company’s recent announcement involving the commercial launch of an entirely new service line called BioPharmaceutical Contract Services. Mr. Schumacher explained that in December 2017, the Company purchased the patent estate of Barofold, Inc. that had spent around $25 million to develop technology involving pressure to control and improve protein molecules being used to make drugs. The patents purchased from Barofold allow the Company to exclusively use different levels of pressure to help fix problems that biopharmaceutical companies often run into as they try to manufacture new protein-based drugs, a very large and growing market with over 200 such drugs already on the market and hundreds more in development. Two of the major problems encountered by such manufacturers are (i) the proteins stick together (aggregation) thus making them not useful as drugs, and (ii) the proteins are “misfolded” (their structure is incorrect). Both of these issues could potentially cause the manufacturers to discard millions of dollars of product from production lots that have aggregation or misfolding issues. Sometimes these issues are so bad that biopharma companies can’t even get the drug to market in the first place. The good news is that PBI’s new Barofold platform can sometimes fix these issues. This is the basis of PBI’s new biopharmaceutical services business, which the Company believes will add significantly to the Company’s revenue in 2019 and beyond.
Mr. Schumacher stated, “We’re going to start advertising, talking to companies, and actively bringing in business, because we know we can help a number of companies who are struggling with protein-based drugs in development get to market. We also believe we can help companies that are already on the market stay on the market, should they encounter aggregation or misfolding issues, as often occurs during manufacturing.”
Mr. Jolly then inquired about the numerous scientific articles published during 2018 that highlighted the benefits of the Company’s Pressure Cycling Technology (PCT) platform. Mr. Schumacher explained that scientific publications from peers are highly respected among researchers and that the fact that over 20 publications were released during 2018 regarding PBI’s PCT technology, some from globally-renowned protein and nucleic acid scientists, will add great support to PBI’s sales and marketing efforts, and should help the Company as it looks to increase its revenue during 2019 and beyond.
Mr. Schumacher closed by stating, “We are a time-tested company with patents, products, a tremendous customer base, an expanding market, and increasing sales. We have struggled a bit over the past few years for a number of different reasons, but we believe we are past that now and on the road to success. Our three pressure-based technology platforms have been vetted by key opinion leaders globally, we have a number of leading scientists in the world who are using our various products, and we expect increased revenue in 2019 from our two new platform technologies (Barofold and UST). We believe that PBIO shareholders have much to be excited about going forward.”
To hear Mr. Schumacher's entire interview with Stock Day, please go here: https://upticknewswire.com/featured-interview...b-pbio-11/
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
About Pressure BioSciences, Inc.
